ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
2022/10/21 by Sofia Ramiro, Sofía Ramiro, Elena Nikiphorou +46 · 32 citations
Medicine · #Spondyloarthritis Studies and Treatments #Rheumatoid Arthritis Research and Therapies #Scoliosis diagnosis and treatment
paper · doi:10.1136/ard-2022-223296
Citations
Cited by
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
- 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
- Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures
- Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: a quasi-experimental study
- Establishing Centers of Excellence for Axial Spondyloarthritis in Latin America: Consensus Recommendations From the REAL-PANLAR Group
- Predicting Treatment Outcomes in Patients With Psoriatic Arthritis or Axial Spondyloarthritis: An Artificial Intelligence–Driven Approach
- Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis. [europepmc]
- Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. [europepmc]
- IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. [europepmc]
- Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. [europepmc]
- The role of WNT and IL-1 signaling in osteoarthritis: therapeutic implications for platelet-rich plasma therapy. [europepmc]
- Korean treatment recommendations for patients with axial spondyloarthritis. [europepmc]
- The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. [europepmc]
- Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort. [europepmc]
- Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study. [europepmc]
- Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. [europepmc]
- Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. [europepmc]
- Regional differences in clinical phenotype of axial spondyloarthritis: results from the International Map of Axial Spondyloarthritis (IMAS). [europepmc]
- Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial. [europepmc]
- Prevalence of anxiety and depression and the association with self-management behaviour in >12 000 patients with inflammatory rheumatic disease: a cross-sectional nationwide study. [europepmc]
- Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs. [europepmc]
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. [europepmc]
- Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity. [europepmc]
- Is sarcopenia a real concern in ankylosing spondylitis? A systematic literature review. [europepmc]
- Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. [europepmc]
- The exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients - A cross-sectional survey. [europepmc]
- Diagnosis, monitoring, and management of axial spondyloarthritis. [europepmc]
- International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe. [europepmc]
- Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. [europepmc]
- Extracellular Vesicles Derived from Ligament Tissue Transport Interleukin-17A to Mediate Ligament-To-Bone Crosstalk in Ankylosing Spondylitis. [europepmc]
- Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis. [europepmc]